296 related articles for article (PubMed ID: 21890582)
1. Modulation of anxiety behavior in the elevated plus maze using peptidic oxytocin and vasopressin receptor ligands in the rat.
Mak P; Broussard C; Vacy K; Broadbear JH
J Psychopharmacol; 2012 Apr; 26(4):532-42. PubMed ID: 21890582
[TBL] [Abstract][Full Text] [Related]
2. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
[TBL] [Abstract][Full Text] [Related]
3. Examining the role of oxytocin in the interoceptive effects of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') using a drug discrimination paradigm in the rat.
Broadbear JH; Tunstall B; Beringer K
Addict Biol; 2011 Apr; 16(2):202-14. PubMed ID: 21070509
[TBL] [Abstract][Full Text] [Related]
4. Characterization of receptors mediating contraction of the rat isolated small mesenteric artery and aorta to arginine vasopressin and oxytocin.
Stam WB; Van der Graaf PH; Saxena PR
Br J Pharmacol; 1998 Oct; 125(4):865-73. PubMed ID: 9831926
[TBL] [Abstract][Full Text] [Related]
5. Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist.
Ring RH; Schechter LE; Leonard SK; Dwyer JM; Platt BJ; Graf R; Grauer S; Pulicicchio C; Resnick L; Rahman Z; Sukoff Rizzo SJ; Luo B; Beyer CE; Logue SF; Marquis KL; Hughes ZA; Rosenzweig-Lipson S
Neuropharmacology; 2010 Jan; 58(1):69-77. PubMed ID: 19615387
[TBL] [Abstract][Full Text] [Related]
6. Oxytocin treatment alleviates stress-aggravated colitis by a receptor-dependent mechanism.
Cetinel S; Hancioğlu S; Sener E; Uner C; Kiliç M; Sener G; Yeğen BC
Regul Pept; 2010 Feb; 160(1-3):146-52. PubMed ID: 19931575
[TBL] [Abstract][Full Text] [Related]
7. Distinct receptor subtypes mediate arginine vasopressin-dependent ACTH release and intracellular calcium mobilization in rat pituitary cells.
Perdonà E; Arban R; Griffante C
Eur J Pharmacol; 2012 Mar; 679(1-3):16-23. PubMed ID: 22285855
[TBL] [Abstract][Full Text] [Related]
8. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
Manning M; Cheng LL; Stoev S; Wo NC; Chan WY; Szeto HH; Durroux T; Mouillac B; Barberis C
J Pept Sci; 2005 Oct; 11(10):593-608. PubMed ID: 15880385
[TBL] [Abstract][Full Text] [Related]
9. Oxytocinergic regulation of endogenous as well as drug-induced mood.
Broadbear JH; Kabel D; Tracy L; Mak P
Pharmacol Biochem Behav; 2014 Apr; 119():61-71. PubMed ID: 23872370
[TBL] [Abstract][Full Text] [Related]
10. Neurohypophyseal hormones manipulation modulate social and anxiety-related behavior in zebrafish.
Braida D; Donzelli A; Martucci R; Capurro V; Busnelli M; Chini B; Sala M
Psychopharmacology (Berl); 2012 Mar; 220(2):319-30. PubMed ID: 21956239
[TBL] [Abstract][Full Text] [Related]
11. Neurohormonal effects of oxytocin and vasopressin receptor agonists on spinal pain processing in male rats.
Juif PE; Poisbeau P
Pain; 2013 Aug; 154(8):1449-56. PubMed ID: 23707282
[TBL] [Abstract][Full Text] [Related]
12. Mutual regulation of vasopressin- and oxytocin-induced glucagon secretion in V1b vasopressin receptor knockout mice.
Fujiwara Y; Hiroyama M; Sanbe A; Yamauchi J; Tsujimoto G; Tanoue A
J Endocrinol; 2007 Feb; 192(2):361-9. PubMed ID: 17283236
[TBL] [Abstract][Full Text] [Related]
13. Effects of a single administration of oxytocin or vasopressin and their interactions with two selective receptor antagonists on memory storage in mice.
Boccia MM; Kopf SR; Baratti CM
Neurobiol Learn Mem; 1998 Mar; 69(2):136-46. PubMed ID: 9619993
[TBL] [Abstract][Full Text] [Related]
14. Effects of chronic social defeat on behavioral and neural correlates of sociality: Vasopressin, oxytocin and the vasopressinergic V1b receptor.
Litvin Y; Murakami G; Pfaff DW
Physiol Behav; 2011 Jun; 103(3-4):393-403. PubMed ID: 21397619
[TBL] [Abstract][Full Text] [Related]
15. [Arg8]vasotocin excites neurones in the dorsal vagal complex in vitro: evidence for an action through novel class(es) of CNS receptors.
Ingram CD; Tolchard S
J Neuroendocrinol; 1994 Aug; 6(4):415-22. PubMed ID: 7987372
[TBL] [Abstract][Full Text] [Related]
16. Role of ventral hippocampal GABA(A) and NMDA receptors in the anxiolytic effect of carbamazepine in rats using the elevated plus maze test.
Rezvanfard M; Zarrindast MR; Bina P
Pharmacology; 2009; 84(6):356-66. PubMed ID: 19907194
[TBL] [Abstract][Full Text] [Related]
17. CR 2945: a novel CCKB receptor antagonist with anxiolytic-like activity.
Revel L; Mennuni L; Garofalo P; Makovec F
Behav Pharmacol; 1998 May; 9(3):183-94. PubMed ID: 9832933
[TBL] [Abstract][Full Text] [Related]
18. Female oxytocin-deficient mice display enhanced anxiety-related behavior.
Mantella RC; Vollmer RR; Li X; Amico JA
Endocrinology; 2003 Jun; 144(6):2291-6. PubMed ID: 12746288
[TBL] [Abstract][Full Text] [Related]
19. A comparison between Dark Agouti and Sprague-Dawley rats in their behaviour on the elevated plus-maze, open-field apparatus and activity meters, and their response to diazepam.
Mechan AO; Moran PM; Elliott M; Young AJ; Joseph MH; Green R
Psychopharmacology (Berl); 2002 Jan; 159(2):188-95. PubMed ID: 11862348
[TBL] [Abstract][Full Text] [Related]
20. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
Cheng LL; Stoev S; Manning M; Derick S; Pena A; Mimoun MB; Guillon G
J Med Chem; 2004 Apr; 47(9):2375-88. PubMed ID: 15084136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
